Combined Therapy with Direct and Indirect Angiogenesis Inhibition Results in Enhanced Antiangiogenic and Antitumor Effects

Cancer Research

Volumn 63, Issue 24, 2003, Pages 8890-8898

  Abdollahi, Amir ^a,d   Lipson, Kenneth E ^b   Sckell, Axel ^d   Zieher, Heike ^a   Klenke, Frank ^d   Poerschke, Daniel ^a   Roth, Alexandra ^a   Han, Xiaohong ^d   Krix, Martin ^a   Bischof, Marc ^d   Hahnfeldt, Philip ^c   Grone, Hermann Josef ^a   Debus, Juergen ^a,d   Hlatky, Lynn ^c   Huber, Peter E ^a,d  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b SUGEN INC   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ENDOSTATIN; INDOLE DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; PYRROLE DERIVATIVE; SEMAXANIB; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ADENOCARCINOMA; ANGIOGENESIS; ANIMAL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD VESSEL; CANCER COMBINATION CHEMOTHERAPY; CELL DIVISION; CELL INVASION; CELL MIGRATION; CELL MOTION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOLOGY; DENSITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SCREENING; DRUG TOXICITY; ECHOGRAPHY; ENDOTHELIUM CELL; FEMALE; GLIOBLASTOMA; GLIOMA; HEMOPERFUSION; HUMAN; HUMAN CELL; IN VIVO STUDY; INHIBITION KINETICS; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MICROCIRCULATION; MOUSE; MOUSE MUTANT; MOUSE STRAIN; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE TUMOR; TUMOR BLOOD FLOW; VASCULAR ENDOTHELIUM; VASCULARIZATION; XENOGRAFT;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIVISION; CELL MOVEMENT; CELL SURVIVAL; DRUG SYNERGISM; ENDOSTATINS; ENDOTHELIUM, VASCULAR; FEMALE; GLIOBLASTOMA; HUMANS; INDOLES; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICE, SCID; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; PYRROLES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 9144265679     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med., 285: 1182-1186, 1971.
2. Carmeliet, P., and Jain, R. K. Angiogenesis in cancer and other diseases. Nature (Lond.), 407: 249-257, 2000.
3. Folkman, J., Hahnfeldt, P., and Hlatky, L. Cancer: looking outside the genome. Nat. Rev. Mol. Cell Biol., 1: 76-79, 2000.
4. Browder, T., Butterfield, C. E., Kraling, B. M., Shi, B., Marshall, B., O'Reilly, M. S., and Folkman, J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res., 60: 1878-1886, 2000.
5. Herbst, R. S., Madden, T. L., Tran, H. T., Blumenschein, G. R., Jr., Meyers, C. A., Seabrooke, L. F., Khuri, F. R., Puduvalli, V. K., Allgood, V., Fritsche, H. A., Jr., Hinton, L., Newman, R. A., Crane, E. A., Fossella, F. V., Dordal, M., Goodin, T., and Hong, W. K. Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small cell lung cancer. J. Clin. Oncol., 20: 4440-4447, 2002.
6. Huang, S. F., Kim, S. J., Lee, A. T., Karashima, T., Bucana, C., Kedar, D., Sweeney, P., Mian, B., Fan, D., Shepherd, D., Fidler, I. J., Dinney, C. P., and Killion, J. J. Inhibition of growth and metastasis of orthotopic human prostate cancer in athymic mice by combination therapy with pegylated interferon-α-2b and docetaxel. Cancer Res., 62: 5720-5726, 2002.
7. Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., and Kerbel, R. S. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Investig. 105: R15-R24, 2000.
8. Mauceri, H. J., Hanna, N. N., Beckett, M. A., Gorski, D. H., Staba, M. J., Stellato, K. A., Bigelow, K., Heimann, R., Gately, S., Dhanabal, M., Soff, G. A., Sukhatme, V. P., Kufe, D. W., and Weichselbaum, R. R. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature (Lond.), 394: 287-291, 1998.
9. Khan, M. K., Miller, M. W., Taylor, J., Gill, N. K., Dick, R. D., Van Golen, K., Brewer, G. J., and Merajver, S. D. Radiotherapy and antiangiogenic TM in lung cancer. Neoplasia, 4: 164-170, 2002.
10. Pedley, R. B., El Emir, E., Flynn, A. A., Boxer, G. M., Dearling, J., Raleigh, J. A., Hill, S. A., Stuart, S., Motha, R., and Begent, R. H. Synergy between vascular targeting agents and antibody-directed therapy. Int. J. Radiat. Oncol. Biol. Phys., 54: 1524-1531, 2002.
11. Baker, C. H., Solorzano, C. C., and Fidler, I. J. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res., 62: 1996-2003, 2002.
12. O'Reilly, M. S. Targeting multiple biological pathways as a strategy to improve the treatment of cancer. Clin. Cancer Res., 8: 3309-3310, 2002.
13. Jain, R. K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med., 7: 987-989, 2001.
14. Huang, X., Wong, M. K., Yi, H., Watkins, S., Laird, A. D., Wolf, S. F., and Gorelik, E. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein. Cancer Res., 62: 5727-5735, 2002.
15. Qian, C. N., Min, H. Q., Lin, H. L., and Hong, M. H. Combination of angiogenesis inhibitor TNP-470 with cytotoxic drugs in experimental therapy of nasopharyngeal carcinoma. Ann. Otol. Rhinol. Laryngol., 109: 641-645, 2000.
16. Richardson, P. G., Schlossman, R. L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L. P., Doss, D., Kelly, K., McKenney, M., Mechlowicz, J., Freeman, A., Deocampo, R., Rich, R., Ryoo, J. J., Chauhan, D., Balinski, K., Zeldis, J., and Anderson, K. C. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood, 100: 3063-3067, 2002.
17. Rajkumar, S. V., Hayman, S., Gertz, M. A., Dispenzieri, A., Lacy, M. Q., Greipp, P. R., Geyer, S., Iturria, N., Fonseca, R., Lust, J. A., Kyle, R. A., and Witzig, T. E. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J. Clin. Oncol., 20: 4319-4323, 2002.
18. Folkman, J., H. P., and Hlatky, L. The logic of anti-angiogenic gene therapy. In: T. Friedmann (ed.), The Development of Gene Therapy, pp. 1-17. New York: Cold Spring Harbor Laboratory Press, 1998.
19. Yoshiji, H., Harris, S. R., and Thorgeirsson, U. P. Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells. Cancer Res., 57: 3924-3928, 1997.
20. Kerbel, R., and Folkman, J. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer, 2: 727-739, 2002.
21. Nagashima, M., Asano, G., and Yoshino, S. Imbalance in production between vascular endothelial growth factor and endostatin in patients with rheumatoid arthritis. J. Rheumatol., 27: 2339-2342, 2000.
22. Asai, K., Kanazawa, H., Otani, K., Shiraishi, S., Hirata, K., and Yoshikawa, J. Imbalance between vascular endothelial growth factor and endostatin levels in induced sputum from asthmatic subjects. J. Allergy Clin. Immunol., 110: 571-575, 2002.
23. Feldman, A. L., Alexander, H. R., Jr., Yang, J. C., Linehan, W. M., Eyler, R. A., Miller, M. S., Steinberg, S. M., and Libutti, S. K. Prospective analysis of circulating endostatin levels in patients with renal cell carcinoma. Cancer (Phila.), 95: 1637-1643, 2002.
24. Dhar, D. K., Ono, T., Yamanoi, A., Soda, Y., Yamaguchi, E., Rahman, M. A., Kohno, H., and Nagasue, N. Serum endostatin predicts tumor vascularity in hepatocellular carcinoma. Cancer (Phila.), 95: 2188-2195, 2002.
25. Hajitou, A., Grignet, C., Devy, L., Berndt, S., Blacher, S., Deroanne, C. F., Bajou, K., Fong, T., Chiang, Y., Foidart, J. M., and Noel, A. The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells. FASEB J., 16: 1802-1804, 2002.
26. Takahashi, K., Saishin, Y., Saishin, Y., Silva, R. L., Oshima, Y., Oshima, S., Melia, M., Paszkiet, B., Zerby, D., Kadan, M. J., Liau, G., Kaleko, M., Connelly, S., Luo, T., and Campochiaro, P. A. Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachment. FASEB J., 17: 896-898, 2003.
27. Miyashita, M., Tajiri, T., Yanagi, K., Shimizu, T., Futami, R., Sasajima, K., and Tokunaga, A. Serum levels of vascular endothelial growth factor, basic fibroblast growth factor and endostatin in human metastatic liver tumors. Hepatogastroenterology, 50: 308-309, 2003.
28. Funatsu, H., Yamashita, H., Noma, H., Mochizuki, H., Mimura, T., Ikeda, T., and Hori, S. Outcome of vitreous surgery and the balance between vascular endothelial. growth factor and endostatin. Investig Ophthalmol. Vis. Sci., 44: 1042-1047, 2003.
29. Krystal, G. W., Honsawek, S., Kiewlich, D., Liang, C., Vasile, S., Sun, L., McMahon, G., and Lipson, K. E. Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells. Cancer Res., 61: 3660-3668, 2001.
30. Fong, T. A., Shawver, L. K., Sun, L., Tang, C., App, H., Powell, T. J., Kim, Y. H., Schreck, R., Wang, X., Risau, W., Ullrich, A., Hirth, K. P., and McMahon, G. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res., 59: 99-106, 1999.
31. Mendel, D. B., Laird, A. D., Smolich, B. D., Blake, R. A., Liang, C., Hannah, A. L., Shaheen, R. M., Ellis, L. M., Weitman, S., Shawver, L. K., and Cherrington, J. M. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des., 15: 29-41, 2000.
32. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., and Folkman, J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88: 277-285, 1997.
33. Wei, K., Jayaweera, A. R., Firoozan, S., Linka, A., Skyba, D. M., and Kaul, S. Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion. Circulation, 97: 473-483, 1998.
34. Krix M., Kiessling F., Vosseler S., Kiessling I., Le-Huu M., Fusenig N. E., and Delorme S. Comparison of intermittent, bolus-contrast imaging with conventional power Doppler sonography: quantification of tumour perfusion in small animals. Ultrasound Med. Biol, 29: 1093-1103, 2003.
35. Sckell A., Klenke F., Merkle T., Gebhard M. M., and Ewerbeck V. Analysis of angiogenesis, microcirculation, and growth of primary and secondary bone tumors: an experimental study in mice. In: M. Boros (ed), Proceedings of the 37th Congress of the European Society for Surgical Research, pp. 165-168. Bologna: Monduzzi Editore, International Proceedings Division, 2002.
36. Berenbaum, M. C. What is synergy? Pharmacol. Rev., 41: 93-141, 1989.
37. Jain, R. K., Safabakhsh, N., Sckell, A., Chen, Y., Jiang, P., Benjamin, L., Yuan, F., and Keshet, E. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc. Natl. Acad. Sci. USA, 95: 10820-10825, 1998.
38. Eder, J. P., Jr., Supko, J. G., Clark, J. W., Puchalski, T. A., Garcia-Carbonero, R., Ryan, D. P., Shulman, L. N., Proper, J., Kirvan, M., Rattner, B., Connors, S., Keogan, M. T., Janicek, M. J., Fogler, W. E., Schnipper, L., Kinchla, N., Sidor, C., Phillips, E., Folkman, J., and Kufe, D. W. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J. Clin. Oncol., 20: 3772-3784, 2002.
39. Herbst, R. S., Mullani, N. A., Davis, D. W., Hess, K. R., McConkey, D. J., Charnsangavej, C., O'Reilly, M. S., Kim, H. W., Baker, C., Roach, J., Ellis, L. M., Rashid, A., Pluda, J., Bucana, C., Madden, T. L., Tran, H. T., and Abbruzzese, J. L. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J. Clin. Oncol., 20: 3804-3814, 2002.
40. Herbst, R. S., Hess, K. R., Tran, H. T., Tseng, J. E., Mullani, N. A., Charnsangavej, C., Madden, T., Davis, D. W., McConkey, D. J., O'Reilly, M. S., Ellis, L. M., Pluda, J., Hong, W. K., and Abbruzzese, J. L. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J. Clin. Oncol., 20: 3792-3803, 2002.
41. Thomas, J. P., Arzoomanian, R. Z., Alberti, D., Marnocha, R., Lee, F., Friedl, A., Tutsch, K., Dresen, A., Geiger, P., Pluda, J., Fogler, W., Schiller, J. H., and Wilding, G. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J. Clin. Oncol., 21: 223-231, 2003.
42. Ramchandran, R., Karumanchi, S. A., Hanai, J., Alper, S. L., and Sukhatme, V. P. Cellular actions and signaling by endostafin. Crit Rev. Eukaryotic Gene Expr., 12: 175-191, 2002.
43. Fidler, I. J. Angiogenic heterogeneity: regulation of neoplastic angiogenesis by the organ mircroenvironment. J. Natl. Cancer Inst. (Bethesda), 93: 1040-1041, 2001.
44. Bergers, G., Javaherian, K., Lo, K. M., Folkman, J., and Hanahan, D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science (Wash. DC), 284: 808-812, 1999.
45. Yokoyama, Y., Dhanabal, M., Griffioen, A. W., Sukhatme, V. P., and Ramakrishnan, S. Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. Cancer Res., 60: 2190-2196, 2000.
46. te Velde, E. A., Vogten, J. M., Gebbink, M. F., van Gorp, J. M., Voest, E. E., and Borel, R., I Enhanced antitumour efficacy by combining conventional chemotherapy with angiostatin or endostatin in a liver metastasis model. Br. J. Surg., 89: 1302-1309, 2002.
47. Arriagada, R., Pignon, J. P., and Le Chevalier, T. Initial chemotherapeutic doses and long-term survival in limited small cell lung cancer. N. Engl. J. Med., 345: 1281-1282, 2001.
48. Herbst, R. S., and Kies, M. S. ZD1839 (Iressa) in non-small cell lung cancer. Oncologist, 7 (Suppl. 4): 9-15, 2002.